Fixed-Oil Excipient Monographs: Development of USP Fixed-Oil Reference Standards - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fixed-Oil Excipient Monographs: Development of USP Fixed-Oil Reference Standards
This article summarizes the development and modernization of the United States Pharmacopeia-National Formulary (USP-NF) fixed-oil excipient monographs. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 102-108

Appendix

Iodine Value



The formula to estimate the iodine value from the Fatty Acid Composition profile (15–17) is:

where

IVmixture = iodine value

PFA = percentage of a fatty acid determined from the Fatty Acid Composition (%)

MW(2I) = atomic weight of two iodine atoms that are theoretically added to one double bond, 253.81

Ndb = number of double bonds

MW(FA) = molecular weight of the fatty acid.

The calculated iodine values for oleic acid, linoleic acid, linolenic acid (each with purity < 99%) using the equation above are 89.9, 181.0, and 237.5, respectively.

Saponification Value

The formula to estimate the saponification value from the Fatty Acid Composition profile (15,17) is:




For triglycerides

where

SVmixture = saponification value

PFA = percentage of a fatty acid determined from the Fatty Acid Composition (%)

MW(KOH)= molecular weight of potassium hydroxide, 56.11

MW(FA) = molecular weight of the fatty acid

MW(Glycerin) = molecular weight of glycerin, 92.09

MW(H2O) = molecular weight of water, 18.02.

About the Authors

Hong Wang* is senior scientific liaison at USP, Rockville, MD, hw@usp.org. Catherine Sheehan is director, excipients, USP. Lawrence H. Block (chair), Richard C. Moreton (vice-chair), Richard H. Wendt, Shireesh P. Apte, and Eric J. Munson are members of the USP 2010–2015 Monographs—Excipients Expert Committee.

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here